54977-92-3|4-Amino-N-benzylbenzamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 54977-92-3 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 54977-92-3 ]

CAS No. :	54977-92-3
Formula :	C₁₄H₁₄N₂O
M.W :	226.27
SMILES Code :	O=C(NCC1=CC=CC=C1)C2=CC=C(N)C=C2
MDL No. :	MFCD00440145
InChI Key :	ZWMQLNXGNSNUEO-UHFFFAOYSA-N
Pubchem ID :	577832

Safety of [ 54977-92-3 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

Application In Synthesis of [ 54977-92-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 54977-92-3 ]

[ 54977-92-3 ] Synthesis Path-Downstream 1~32

1
[ 150-13-0 ]
[ 100-46-9 ]
[ 54977-92-3 ]

References: [1]Green Chemistry,2015,vol. 17,p. 3157 - 3163.
[2]RSC Advances,2015,vol. 5,p. 25789 - 25793.
[3]Journal of Chemical and Engineering Data,1982,vol. 27,p. 479 - 481.
[4]Journal of Organic Chemistry,1943,vol. 8,p. 168,171.

2
[ 54977-92-3 ]
[ 121-60-8 ]
4-[(<i>N</i>-acetyl-sulfanilyl)-amino]-benzoic acid benzylamide [ No CAS ]

References: [1]Journal of the Chemical Society,1945,p. 732,735.

3
[ 50-00-0 ]
[ 54977-92-3 ]
[ 108191-13-5 ]

References: [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 1214 - 1218.

4
[ 2585-26-4 ]
[ 54977-92-3 ]

Yield	Reaction Conditions	Operation in experiment
91%		General procedure: The aromatic nitro compounds are dissolved in ethyl acetate and SnCl2 × 2H2O (1.125 g/mmol) is added. The reaction mixture is heated under reflux for at least 2 h. The reaction is monitored by thin layer chromatography. When the reaction is completed, the batch is cooled. A solution of NaHCO3 is then added until pH 7-8 is reached. The organic layer is separated and the aqueous residue is washed three times with ethyl acetate. The combined organic layers are washed with brine and dried over MgSO4. The solvent is removed in vacuo to obtain the crude product.
85%	With hydrogenchloride; tin; In ethanol; water;Reflux;	General procedure: Concentrated HCl (10-15 ml) was added slowly to a mixture of 4-nitrobenzenesulfonamide or 4-nitrobenzamide analog (13a-q,1.4 mmol, 1 eq) and Sn granules (2-2.5 eq) in ethanol (10 mL). The reaction mixture was refluxed for 3.5-6 h. When the TLC plates howed that there is no more starting material left, the reaction mixture was cooled down to rt. NaOH (30% or 5M, aq) was added to the mixture until it became basic. The mixture was extracted with EA or DCM and the organic layer was dried with Na2SO4. The solvent was evaporated. The product was purified with column chromatography when required. 4.6.4.23 4-Amino-N-benzylbenzamide (14f) From 13f (0.89 g, 3.5 mmol) with general procedure B. Light yellow solid (0.67 g, 85%). 1H NMR (DMSO-d6): δ 4.42 (2H, d, J = 6.0 Hz), 5.60 (2H, s), 6.54 (2H, d, J = 8.6 Hz), 7.21 (1H, m), 7.29 (4H, m), 7.61 (2H, d, J = 8.6 Hz), 8.54 (1H, t, J = 5.9 Hz).

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 3717 - 3731.
[2]European Journal of Medicinal Chemistry,2016,vol. 107,p. 119 - 132.
[3]Organic Letters,2021,vol. 23,p. 2742 - 2747.
[4]Journal of Medicinal Chemistry,1984,vol. 27,p. 779 - 782.
[5]Journal of Chemical Research,2006,p. 223 - 224.
[6]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 856 - 860.

Yield	Reaction Conditions	Operation in experiment
92%	With trifluoroacetic acid; In dichloromethane; at 20℃; for 5.0h;	General procedure: 20 ml of trifluoroacetic acid are added to a solution of 4-[N-(tert-butoxycarbonyl)amino]-N-(tert-butyl)benzylamide (0.20 g, 0.52 mol) in DCM (20 ml); the reaction mixture is maintained with constant stirring and at room temperature for 5 h. Then, the solvent is removed at reduced pressure, and the crude reaction product is dissolved in a 1M DCM/NaOH biphasic system (1:1) (20 ml); the mixture is stirred for 10 min. Then, it is extracted with DCM, and the organic extracts are dried over MgSO4. The solvent is removed at reduced pressure obtaining III as a white solid (0.13 g, 90%). 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J=8.3 Hz, 2H, H-3',5'), 7.37 (d, J=8.3 Hz, 2H, H-3',5'), 7.29 (d, J=8.4 Hz, 2H, H-2',6'), 6.64 (d, J=8.4 Hz, 2H, H-2,6), 4.59 (d, J=5.4 Hz, 2H, NHCH2), 1.32 (s, 6H, CH3). 13C NMR (75 MHz, CDCl3) δ 167.0 (CO), 150.5, 149.5, 135.5, 128.7 (C-3,5), 127.7 (C-3',5'), 125.6 (C-2',6'), 124.0, 114.1 (C-2,6), 43.7 (CH2), 34.5 (C), 31.3 (3CH3). HPLC gradient of 15-95% CH3CN/H2O in 5 min, tr=4.67 min, m/z [M+H]+=283. Theoretical elemental analysis C18H22N2O: C, 76.56; H, 7.85; N, 9.92; experimental elemental analysis C, 76.71; H, 8.10; N, 9.94.
		Some further compounds of the amino-benzamide type contemplated within this invention are the following: 1. 4-amino-N-phenyl-benzamide; [4-aminobenzanilide] 2. 4-amino-N-cyclohexyl-benzamide 3. 4-amino-N-amyl-benzamide; [4-amino-N-(n-pentyl)-benzamide] 4. 4-amino-N-benzyl-benzamide 5. 4-amino-N,N-(di-n-propyl)-benzamide 6. 4-amino-N-(n-hexyl)-benzamide 7. 4-amino-N-(n-butyl)-benzamide

7
[ 100-46-9 ]
[ 62-23-7 ]
[ 54977-92-3 ]

References: [1]Tetrahedron Letters,2000,vol. 41,p. 6531 - 6535.

8
[ 1194-98-5 ]
[ 54977-92-3 ]
N-Benzyl-4-[1-(2,5-dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 441 - 452.

9
[ 327037-11-6 ]
[ 54977-92-3 ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 441 - 452.
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 6639 - 6652.

10
[ 66493-39-8 ]
[ 54977-92-3 ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 441 - 452.
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 6639 - 6652.

11
[ 54977-92-3 ]
<i>N</i>-benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 441 - 452.

12
[ 150-13-0 ]
4-benzylidene-2-phenyl-5-imidazolone-acetic acid (pseudo)halide [ No CAS ]
[ 54977-92-3 ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 441 - 452.

13
[ 122-04-3 ]
5-oxymethyl-2-phenyl-oxazolidine [ No CAS ]
[ 54977-92-3 ]

References: [1]Journal of Medicinal Chemistry,1984,vol. 27,p. 779 - 782.

14
[ 100-46-9 ]
tertiarybutyl iodide [ No CAS ]
[ 54977-92-3 ]

References: [1]Journal of Medicinal Chemistry,1984,vol. 27,p. 779 - 782.

15
[ 54977-92-3 ]
4-sulfanilylamino-benzoic acid benzylamide [ No CAS ]

References: [1]Journal of the Chemical Society,1945,p. 732,735.

16
[ 122-04-3 ]
[ 100-46-9 ]
[ 54977-92-3 ]

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 3717 - 3731.
[2]Organic Letters,2021,vol. 23,p. 2742 - 2747.

17
[ 54977-92-3 ]
[ 611-73-4 ]
[ 1618080-55-9 ]

References: [1]Chemical Communications,2014,vol. 50,p. 7881 - 7884.

18
[ 54977-92-3 ]
[ 611-73-4 ]
[ 1618080-47-9 ]

References: [1]Chemical Communications,2014,vol. 50,p. 7881 - 7884.

19
[ 83991-57-5 ]
[ 54977-92-3 ]
C₃₄H₃₃N₅O₂ [ No CAS ]